In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. - Wikidata - wikimedia - TriplyDB

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

http://www.wikidata.org/entity/Q39030433

about

Novel drugs that target the metabolic reprogramming in renal cell cancer Mitochondrial metabolic remodeling in response to genetic and environmental perturbations Hypoxia and metabolic adaptation of cancer cells Cancer Metabolism and Drug Resistance Dysregulated metabolism contributes to oncogenesis Oncogenes strike a balance between cellular growth and homeostasis Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters Metabolic consequences of oncogenic IDH mutations Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation.Vascular endothelial growth factor signaling in hypoxia and inflammation.Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.From Krebs to clinic: glutamine metabolism to cancer therapy.A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.HIF1α and HIF2α exert distinct nutrient preferences in renal cells Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis 13C isotope-assisted methods for quantifying glutamine metabolism in cancer cells.Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.Metabolic Signatures of Human Breast Cancer.Hypoxia drives transient site-specific copy gain and drug-resistant gene expression.Regulation of Stem Cell Fate by ROS-mediated Alteration of Metabolism.Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.MYC-induced reprogramming of glutamine catabolism supports optimal virus replication.Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A.IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism

P2860

Q26740187-93015A0D-7AC1-4F3A-918F-24DF62AAE005 Q26747718-A12F3A4A-DBC1-4B44-B2CE-F557D75988AE Q26774856-B9D5AC65-5B29-490D-972B-CDDCCDA0F60B Q26782042-CD0AF072-DEE6-4BE4-ABC6-ECDCAD590954 Q26784630-DA30A80F-3F3B-4B89-8A33-82294379E9DD Q26798085-2A2DE50B-860A-490F-8436-50B79167A48C Q26851787-04A62AC6-4F24-481C-AA65-D90D78F99349 Q28072798-366EBB84-C140-422E-9939-A7B75A1DC3C9 Q28081811-49AA13EF-BE33-48C4-970C-A6D406665F52 Q28082949-F483EAB2-EAA3-4371-BB6B-8BE7E2298F32 Q30316645-876B75E9-1AAA-47E1-9D34-586811F617A4 Q30928926-75E2981A-F98D-4AE5-A020-C09C141A4AAC Q33608219-5DD89885-4A2C-446F-BF55-4DF62080F814 Q33685916-BD0C189C-7F71-4687-A4FE-287439DC3422 Q33721685-844879BE-1DA8-4D07-952E-0700D8C7FFEE Q33756739-A05818A2-1A82-4F67-8D1A-7D6CCE7BC075 Q33766729-3BF1E882-9BB5-45D9-B9E2-965B007579D1 Q33834498-41CC8ABE-E72D-4B60-A9E7-B25C04A509BB Q34041458-59FC796D-2B76-490B-92E1-47B3752F5879 Q34117812-B4C63783-61E6-4708-84B2-E66046EF0839 Q34431793-695BB6BC-7D09-488A-97B0-70099FA008DB Q34691457-FB1EFF64-9CB6-45B6-8F2A-628AE4446D40 Q34866624-4F970E67-25AE-42F6-BA52-00301DB37D0E Q35176799-8B2DC0DF-0072-486B-99FC-3C5A979C3155 Q35183953-0DCEC24A-2B6C-42C8-BC47-55AABA650311 Q35359580-8D0DE65E-2348-4713-88BE-A9D5EB970D62 Q35591773-286BDB20-B81E-4F6E-A85C-774A056BFD0D Q35627478-D7A495F7-2B06-4E7D-B6B9-B2B28285E5F8 Q35635451-E1EF71B3-9872-4223-B8F2-38D9AA698294 Q35653660-6B595861-8EB7-4E71-B23E-7264B4A98A28 Q35719850-426B0F19-3EC1-4339-BE98-E1FBF753955F Q35752074-183E8CB0-FC77-4E4F-BA43-5DD92A621594 Q35920909-359FC9E4-AC6A-4906-AA2D-8FB2CA16C940 Q36066391-EB19D8DA-E14E-4031-AA9A-C568E72DCE71 Q36320460-29373BA1-5B2D-4D51-AE99-8D5E4B2E4AF0 Q36330223-97E2F196-C9EF-4D97-8E49-62C131F49731 Q36696610-79330494-9BEA-4848-AA9A-6DD04784A35C Q36812466-314BE0C3-C1DA-438E-85B6-4E10DDBECBA6 Q36916313-4B7F28A9-7645-4313-A896-BB18D66C3DF3 Q36948088-937BB824-61BD-4603-AA33-59DE919E5234

P2860

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

http://www.wikidata.org/entity/Q39030433

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@en

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@nl

type

label

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@en

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@nl

prefLabel

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@en

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@nl

P1433

Q39030433-DBE53152-5404-4779-8076-3C0D7E482E04

P1476

Q39030433-552C2D11-80FB-459F-9383-1D4632612AAB

P2093

Q39030433-369870C5-DAAF-4765-BA97-AA2B3DFA6940

Q39030433-4C886BBF-4C7C-44B4-9F01-1F679C3E9600

Q39030433-62F363DA-2661-4CC9-B0C3-F882B4EB6C2E

Q39030433-7BB89C08-450D-4D45-9BAC-1D165502D913

Q39030433-82AED3CF-47C9-4C5A-80D1-37C9C1E93CF8

Q39030433-88D81963-872A-4880-8E62-4DB1DD9E78BD

Q39030433-9373CA47-0C68-44B0-96A9-7708C319C457

Q39030433-9DD30FD3-5309-4B05-A6DD-6DAE89496F43

Q39030433-B8A38D87-7C90-41D6-BB2E-5FCE8FD51A73

Q39030433-DCD98CFD-50AB-4BE6-A939-782B0DE0837B

P2860

Q39030433-0275B95A-F51D-4EED-95D9-B2D5386C5CD3

Q39030433-0688A1D5-7A77-41F4-A172-21FC4BAB667D

Q39030433-0784C9C4-20E6-48C6-B2DC-D2D335331CF2

Q39030433-12ED8BAC-01BB-4B33-B818-0B8CC9728D01

Q39030433-17F0DBD4-5B81-4CF6-B178-7CBA13D6CB2E

Q39030433-18B76DAC-CCFF-4CEF-BD74-A0A96041BA0F

Q39030433-19216E98-A59F-49D2-A2C4-D081B9350321

Q39030433-1DE0837F-2510-4036-A7EB-6131C8B57475

Q39030433-22D293AA-032B-4AF3-B7DA-4136DCE4FBBD

Q39030433-23D69385-3442-4C4B-8417-23F73079BC6E

P304

Q39030433-2B3ADABC-1864-427E-BC86-2A0C071D6C7C

P31

Q39030433-A5CF9B17-5E09-4113-B674-498F1B12E688

P356

Q39030433-2E951A6F-6003-40ED-BDFA-BC14152D9202

P433

Q39030433-CA0A1191-2C07-47C1-B9AC-27A22BE554F2

P478

Q39030433-2D17373F-319D-4182-BFFD-5D2678340111

P577

Q39030433-36D8AA07-D482-4F84-86A7-3CE69D97AF74

P5875

Q39030433-638672B5-A953-4ACE-B28C-B2CC3551A7F7

P698

Q39030433-1D7788C5-9F7D-4CFE-948A-ABF8B5CBD4D9

P932

Q39030433-AC2AA013-D642-4B47-AF15-A432A10E555F

P356

J.CMET.2013.02.002

P1433

Cell Metabolism

P1476

In vivo HIF-mediated reductive ...... ells to glutamine deprivation.

@en

P2093

Alexandra Arreola

http://www.w3.org/2001/XMLSchema#string

Ana M Metelo

http://www.w3.org/2001/XMLSchema#string

Aria Olumi

http://www.w3.org/2001/XMLSchema#string

Gregory Stephanopoulos

http://www.w3.org/2001/XMLSchema#string

Juanjuan Yang

http://www.w3.org/2001/XMLSchema#string

Othon Iliopoulos

http://www.w3.org/2001/XMLSchema#string

Paulo A Gameiro

http://www.w3.org/2001/XMLSchema#string

Pilar López-Larrubia

http://www.w3.org/2001/XMLSchema#string

Rania Baker

http://www.w3.org/2001/XMLSchema#string

Rocio Pérez-Carro

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of cellular metabolism by protein lysine acetylation

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

The redox state of free nicotinamide-adenine dinucleotide phosphate in the cytoplasm of rat liver

Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL

HIF-1: upstream and downstream of cancer metabolism

MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

P304

372-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CMET.2013.02.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235893624

http://www.w3.org/2001/XMLSchema#string

P698

23473032

http://www.w3.org/2001/XMLSchema#string

P932

4003458

http://www.w3.org/2001/XMLSchema#string